Methods of priming a plasma processing system are disclosed. The plasma processing system has a number of different fluid flow circuits that are defined by sources of fluid, fluid flow paths, waste containers, a mixer, a separator, valves and a pump. A first fluid circuit is flushed, where the first fluid circuit is defined by a source of a first fluid, a first valve positioned between the source of the first fluid and the first fluid flow path, a second valve positioned between the first fluid flow path and the second fluid flow path, a first pump positioned between the second fluid flow path and the third fluid flow path, and a first waste container in fluid communication with the third fluid flow path. A second fluid circuit is then flushed by closing and opening certain valves.

The present disclosure provides apparatuses and systems for delivering a measureable absorbed-dose of a gaseous activating agent to a fluid including a biological liquid and/or cells. The apparatuses or systems include a gas-fluid contact device configured to controllably rotate or oscillate a control member having an interior surface in contact with the fluid and a control system configured to control rotation or oscillation of the contact member by the gas-fluid contact device. In some embodiments, the control system is further configured to control absorption of the gaseous activating agent by the fluid. The present disclosure also provides methods of treating a fluid including a biological liquid or cells with a gaseous activating agent to controllably activate the fluid.

In some embodiments, the present invention generally relates to the separation of blood within a device to form plasma or serum. In some embodiments, the present invention generally relates to the removal of fluids, such as blood, contained within a device. In one aspect, the present invention is generally directed to systems and methods for receiving blood from a subject and processing the blood to form plasma or serum. For example, a device may be applied to the skin of a subject to receive blood from the subject and pass the blood through a separation membrane, which separates the blood into plasma and a portion concentrated in blood cells. As another example, blood or plasma may be allowed to clot within the device and serum (the unclotted portion of the blood) may be withdrawn from the device. The device may contain, in some cases, a vacuum source such as a pre-packaged vacuum to facilitate receiving of blood and/or passage of the blood through the separation membrane to produce plasma or serum. In certain embodiments, plasma, serum, or other fluids may be removed from the device by inserting a needle into a portion of the device that has reduced pressure, expelling gas into the device through the needle, then receiving plasma, serum, or other fluids through the needle.

A system for reducing toxicity from intravascular triggered drug delivery includes a chamber comprising an inflow port, an outflow port, and a filter positioned upstream of the outflow port. A trigger module is configured to trigger the release of a drug from an intravascular triggered drug delivery system present in blood in the chamber. A method for reducing toxicity from intravascular triggered drug delivery includes the steps of removing blood comprising an intravascular triggered drug delivery system from a patient's vascular system and delivering the blood to a chamber, applying a trigger to the blood to release a drug from the intravascular triggered drug delivery system, filtering the drug from the blood, and returning the filtered blood to the patient.

A process for removing Co.sup.2+, Pb.sup.2+, Cd.sup.2+ and Cr.sup.3+ toxins from bodily fluids is disclosed. The process involves contacting the bodily fluid with an ion exchange composition to remove the metal toxins in the bodily fluid, including blood and gastrointestinal fluid. Alternatively, blood can be contacted with a dialysis solution which is then contacted with the ion exchange composition. The ion exchange compositions are represented by the following empirical formula:
A.sub.mZr.sub.aTi.sub.bSn.sub.cM.sub.dSi.sub.xO.sub.y. A composition comprising the above ion exchange compositions in combination with bodily fluids or dialysis solution is also disclosed. The ion exchange compositions may be supported by porous networks of biocompatible polymers such as carbohydrates or proteins.

The present invention relates to a multi-stage blood purification apparatus designed to remove substances from a bodily fluid of a subject. In one aspect, the present invention relates to a sorbent stage containing a sorbent material by which a substance, or substances, is removed from a bodily fluid when in contact with the bodily fluid. In another aspect, the present invention provides a multi-stage blood purification apparatus containing a sorbent stage and a membrane stage. Further, methods of purifying a bodily fluid utilizing apparatuses of the present disclosure are provide.

The present invention relates to a method for preparing a growth-factors containing platelet releasate from a fluid mammalian platelet concentrate, comprising the consecutive steps of subjecting the platelet concentrate to a pathogen reduction step to disrupt non-enveloped viruses; subjecting the platelet concentrate to an activation step to cause the platelets to release growth factors; recovering a fibrinogen depleted fluid platelet releasate; subjecting the fibrinogen depleted fluid platelet releasate to a second pathogen concentration reduction step to disrupt enveloped viruses; subjecting the platelet releasate to sterile filtering and recovering a filtrate liquid containing the growth factors.

The platelet releasate obtained with the method of the present invention may be used as a therapeutic agent to enhance the proliferation of multi lineage cells in regenerative medicine and in the management of non healing wounds and resistant ulcers. The second indication is as a substitute to fetal bovine serum in in cell culture media.

Various examples are provided for highly selective and ultra-high throughput filtration using bilayer two-dimensional (2D) material laminates and highly absorptive medium of 2D material laminates or solution dispersions. In one example, a 2D material bilayer membrane includes a first membrane layer; an interlinking layer of interlinking molecules disposed on the first membrane layer; and a second membrane layer disposed on the interlinking layer. The interlinking molecules electrostatically or covalently interlink the second membrane layer and first membrane layer.

This invention is directed to a process for depleting one or more targeted substances such as toxins, proteins such as one or more immune checkpoint inhibitors (ICI), or a combination thereof from a subject. Immune checkpoint inhibitors (ICI), such as PD-1 protein, PD-1 ligand (PD-L1), CTLA-4, LAG-3, TIM3 and others are known to be involved in inhibition of T-cell activation in tumor patients. This invention is also directed to a device for depleting ICI such as PD-1 protein, PD-1 ligand (PD-L1) including soluble PD-L1 (sPD-L1), PD-L2, CTLA-4 including soluble form sCTLA-4, LAG-3, TIM3, or toxins from a subject. This invention is further directed to the use of the process and the devices for treating medical conditions such as cancers, other diseases and substance overdose.

A hemodialysis system configured to purge air from a blood circuit comprising: a dialyzer; a dialysis fluid circuit operable with the dialyzer via dialysis fluid inlet and outlet lines; the blood circuit operable with the dialyzer and including an arterial line, a venous line, a blood pump operable with the arterial line upstream of the dialyzer, and a physiologically acceptable fluid source in fluid communication with the arterial line upstream of the blood pump; and an air purging scheme wherein, with the dialysis fluid inlet and outlet lines connected to the dialyzer, air is purged using dialysis fluid or other physiologically acceptable fluid pumped by at least one of the fresh or used dialysis fluid pumps from the dialysis fluid circuit, through the dialyzer, into the blood circuit, in combination with dialysis fluid or other physiologically acceptable fluid from the source introduced directly into the blood circuit.